Risk factor modification: another win for our fight against atrial fibrillation

Affiliations

¹ Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN, USA.
² Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.

Comment

Lin Y Chen et al. Europace. 2019.

. 2019 Apr 1;21(4):527-528.

doi: 10.1093/europace/euz010.

¹ Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN, USA.
² Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.

No abstract available

Comment on

Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study.
De With RR, Rienstra M, Smit MD, Weijs B, Zwartkruis VW, Hobbelt AH, Alings M, Tijssen JGP, Brügemann J, Geelhoed B, Hillege HL, Tukkie R, Hemels ME, Tieleman RG, Ranchor AV, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC. De With RR, et al. Europace. 2019 Apr 1;21(4):563-571. doi: 10.1093/europace/euy311. Europace. 2019. PMID: 30629160 Clinical Trial.